Direct health care costs of managing perianal Crohn’s Disease in a population based cohort

References

• Burisch J, Vardi H, Schwartz D, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020;5(5):454–464.
   PubMed Web of Science ®Google Scholar
• Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156(1):254–272.e11.
   PubMed Web of Science ®Google Scholar
• Niewiadomski O, Studd C, Hair C, et al. Health care cost analysis in a population-based inception cohort of inflammatory bowel disease patients in the first year of diagnosis. J Crohns Colitis. 2015;9(11):988–996.
   PubMed Web of Science ®Google Scholar
• Section PIM. PBS expenditure and prescriptions report 1 July 2018 to 30 June 2019. In: Section PIM, editor. Australia: Department of Health; 2019.
   Google Scholar
• Dixit SK, Sambasivan M. A review of the Australian healthcare system: a policy perspective. SAGE Open Med. 2018;6:2050312118769211.
   Web of Science ®Google Scholar
• Duricova D, Pedersen N, Elkjaer M, et al. Overall and cause-specific mortality in Crohnʼs disease: a meta-analysis of population-based studies. Inflamm Bowel Dis. 2010;16(2):347–353.
   PubMed Web of Science ®Google Scholar
• Xu F, Dahlhamer J, Zammitti E, et al. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease - United States, 2015 and 2016. Atlanta (GA): U.S. Center for Disease Control; 2018. p. 190–195.
   Google Scholar
• Huoponen S, Blom M. A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PloS One. 2015;10(12):e0145087.
   PubMed Web of Science ®Google Scholar
• Pillai N, Dusheiko M, Burnand B, et al. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12(10):e0185500.
   PubMed Web of Science ®Google Scholar
• Zhao M, Lo BZS, Vester-Andersen MK, et al. A 10-year follow-up study of the natural history of perianal Crohn’s disease in a Danish population-based inception Cohort. Inflamm Bowel Dis. 2019;25(7):1227–1236.
   PubMed Web of Science ®Google Scholar
• Park SH, Aniwan S, Scott Harmsen W, et al. Update on the natural course of fistulizing perianal Crohn’s disease in a population-based cohort. Inflamm Bowel Dis. 2019;25(6):1054–1060.
   PubMed Web of Science ®Google Scholar
• Eglinton TW, Barclay ML, Gearry RB, et al. The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum. 2012;55(7):773–777.
   PubMed Web of Science ®Google Scholar
• Göttgens KW, Jeuring SF, Sturkenboom R, et al. Time trends in the epidemiology and outcome of perianal fistulizing Crohn’s disease in a population-based cohort. Eur J Gastroenterol Hepatol. 2017;29(5):595–601.
   PubMed Web of Science ®Google Scholar
• Nordholm-Carstensen A, Qvist N, Højgaard B, et al. DOP76 prevalence and healthcare costs of perianal fistulas in Crohn’s disease in a nationwide cohort. J Crohn’s Colitis. 2019;13(Suppl_1):S076.
   Google Scholar
• Inflammatory Bowel Disease National Action Plan 2019. In: Department of Health, editor. Australia: Commonwealth of Australia; 2019. p. 34.
   Google Scholar
• Bhatia R, Yeoh SW, Vaz K, et al. Inflammatory bowel disease incidence, prevalence and 12-month initial disease course in Tasmania, Australia. Intern Med J. 2019;49(5):622–630.
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Targownik LE, Kanwal F, et al. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. Gastroenterology. 2004;127(2):403–411.
   PubMed Web of Science ®Google Scholar
• Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131(3):719–728.
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. Australian refined diagnosis-related groups (AR-DRG) data cubes. [Internet] [cited 2017 Oct 4]. Available from: https://reporting.aihw.gov.au/Reports/openRVUrl.do
   Google Scholar
• Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289–297.
   PubMed Web of Science ®Google Scholar
• van der Valk ME, Mangen M-JJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63(1):72–79.
   PubMed Web of Science ®Google Scholar
• Kuenzig ME, Benchimol EI, Lee L, et al. The impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol. 2019;2(Suppl_1):S17–S33.
   PubMedGoogle Scholar
• Kuenzig ME, Lee L, El-Matary W, et al. The impact of inflammatory bowel disease in Canada 2018: indirect costs of IBD care. J Can Assoc Gastroenterol. 2019;2(Suppl 1):S34–S41.
   PubMedGoogle Scholar
• Chaparro M, Zanotti C, Burgueño P, et al. Health care costs of complex perianal fistula in Crohn’s disease. Dig Dis Sci. 2013;58(12):3400–3406.
   PubMed Web of Science ®Google Scholar
• Martín-Arranz MD, Pascual Migueláñez I, Marijuán JL. P515 Costs associated with the management of refractory complex perianal fistulas in patients with Crohn’s disease. J Crohn’s Colitis. 2019;13(Suppl_1):S370–S371.
   Google Scholar
• Odes S, Vardi H, Friger M, et al. Effect of phenotype on health care costs in Crohn’s disease: a European study using the Montreal classification. J Crohns Colitis. 2007;1(2):87–96.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
   PubMed Web of Science ®Google Scholar
• Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn’s disease. J Crohns Colitis. 2017;11(5):549–555.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45(7):933–940.
   PubMed Web of Science ®Google Scholar